Treatment  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
rheumatic  ||| S:13 E:23 ||| JJ
diseases  ||| S:23 E:32 ||| NNS
and  ||| S:32 E:36 ||| CC
hepatitis  ||| S:36 E:46 ||| NNP
B  ||| S:46 E:48 ||| NNP
virus  ||| S:48 E:54 ||| NN
coinfection  ||| S:54 E:66 ||| VBD
We  ||| S:66 E:69 ||| PRP
often  ||| S:69 E:75 ||| RB
encounter  ||| S:75 E:85 ||| VB
rheumatological  ||| S:85 E:101 ||| JJ
patients  ||| S:101 E:110 ||| NNS
coinfected  ||| S:110 E:121 ||| VBN
with  ||| S:121 E:126 ||| IN
hepatitis  ||| S:126 E:136 ||| NNP
B  ||| S:136 E:138 ||| NNP
in  ||| S:138 E:141 ||| IN
daily  ||| S:141 E:147 ||| JJ
practice ||| S:147 E:155 ||| NN
.  ||| S:155 E:157 ||| .
In  ||| S:157 E:160 ||| IN
this  ||| S:160 E:165 ||| DT
paper ||| S:165 E:170 ||| NN
,  ||| S:170 E:172 ||| ,
we  ||| S:172 E:175 ||| PRP
will  ||| S:175 E:180 ||| MD
discuss  ||| S:180 E:188 ||| VB
the  ||| S:188 E:192 ||| DT
basic  ||| S:192 E:198 ||| JJ
characteristics  ||| S:198 E:214 ||| NNS
of  ||| S:214 E:217 ||| IN
the  ||| S:217 E:221 ||| DT
virus  ||| S:221 E:227 ||| NN
of  ||| S:227 E:230 ||| IN
hepatitis  ||| S:230 E:240 ||| NNP
B ||| S:240 E:241 ||| NNP
,  ||| S:241 E:243 ||| ,
course  ||| S:243 E:250 ||| NN
of  ||| S:250 E:253 ||| IN
infection ||| S:253 E:262 ||| NN
,  ||| S:262 E:264 ||| ,
the  ||| S:264 E:268 ||| DT
safety  ||| S:268 E:275 ||| NN
of  ||| S:275 E:278 ||| IN
rituximab ||| S:278 E:287 ||| NN
,  ||| S:287 E:289 ||| ,
tocilizumab ||| S:289 E:300 ||| NN
,  ||| S:300 E:302 ||| ,
abatacept  ||| S:302 E:312 ||| JJ
treatment  ||| S:312 E:322 ||| NN
and  ||| S:322 E:326 ||| CC
therapeutic  ||| S:326 E:338 ||| JJ
recommendations  ||| S:338 E:354 ||| NNS
in  ||| S:354 E:357 ||| IN
management  ||| S:357 E:368 ||| NN
of  ||| S:368 E:371 ||| IN
patients  ||| S:371 E:380 ||| NNS
with  ||| S:380 E:385 ||| IN
rheumatic  ||| S:385 E:395 ||| JJ
diseases ||| S:395 E:403 ||| NNS
.  ||| S:403 E:405 ||| .
